Sandoz officially recognized as Global Top Employer 2020

  • Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally
  • People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition
  • Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work

Holzkirchen, January 30, 2020 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” …

/by

Sandoz officially recognized as Global Top Employer 2020

  • Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally
  • People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition
  • Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work

Holzkirchen, January 30, 2020 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” …

/by

Novartis 2019 Financial Results

Download the media release
English (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB)

Condensed financial report (PDF 0.7 MB) …

/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis at the World Economic Forum Annual Meeting Davos 2020

Planting a Better Future

Novartis CEO Vas Narasimhan moderated a panel of some of the youngest leaders to discuss which actions should leaders prioritize to secure prosperity for the next generation.

Watch the session

/by

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

  • Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1
     
  • Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population
     
  • Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, …
/by

Novartis @ J.P Morgan 2020

This conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Novartis CEO Vas Narasimhan addressed the conference on Monday January 13, 2020.

Watch the webcast 

…

/by

Sourcing innovation, strategically

Looking for the latest trends in biotech? Phil Gotwals has answers. In his former role focused on searching for and evaluating external science and technology at the Novartis Institutes for BioMedical Research (NIBR), he laughingly called himself a “personal shopper” for scientists looking for innovative ways to discover new medicines.

Now Head of Business Development and Licensing (BD&L) at NIBR, Gotwals is thinking more strategically. His eyes are still on the trends, but he’s also delving deeply into the science already in play at NIBR to guide thinking about which of those …

/by